Conference Presentation, Panel, Fireside Chat
Lunch Panel: A Cure for What Ails Us: Celebrating the Impact of Science
- The American Heart Association anticipates a continued decrease in heart disease death rates annually, noting a 36% drop in the past decade, while aiming to reverse lifestyle-driven health trends by mobilizing young investigators to become NIH grant recipients and defining "ideal cardiovascular health" across seven factors.
- Projections indicate that less than 1% of Americans currently achieve ideal cardiovascular health, yet reaching this status at age 50 reduces lifetime cardiovascular event risk to under 5%, contrasting with current statistics where 90% of spending remains stagnant on treatment rather than prevention.
- Obesity and unhealthy diets are identified as escalating risks for elevated blood sugar and diabetes, contributing to a $1 trillion annual cost to the U.S. economy and increasing the likelihood of heart attacks, which the organization views as a national problem in the world's heaviest developed nation.
- Funding challenges for young scientists, whose average age has risen to 35-37, have intensified with grant success rates plummeting to under 20% over the last decade and potentially dropping to 10% or less for new applicants following a $1.7 billion sequester loss.
- The National Center for Advancing Translational Sciences aims to reduce the drug development timeline from 23 years to a faster pace by utilizing biochips for safety testing and repurposing compounds, with expectations that 90% of cystic fibrosis patients could be helped if current phase 2 and 3 trials succeed.
- The FDA seeks to align regulatory expectations with discovery to remove bottlenecks, expecting complex diseases to require integrated diagnostics and therapeutics developed through global partnerships, including capacity building in nations like China and India.
- The CDC expects to deploy emergency supplies for disasters anywhere in the U.S. within 12 hours and to distribute vaccines globally within similar timeframes, aiming to replicate the 320,000 shipments sent during the 2009 H1N1 response.
- Response efforts for the H7N9 avian influenza involve 193 scientists, with kits shipped to dozens of locations, aiming to mitigate a virus that kills one in five affected individuals in China despite not yet spreading efficiently between humans.
- A decade-long "brain initiative" involving the NIH, NSF, and DARPA plans to map brain circuits using optogenomics and "transparent brain" technologies to study function in real time, addressing big data challenges through interdisciplinary collaboration.
- Regenerative medicine is expected to converge stem cell biology, 3D printing, and other technologies to potentially regenerate cardiac tissue and kidneys, offering alternatives to transplants and dialysis within the 21st century.
- Pandemic influenza concerns persist with expectations that a universal vaccine targeting the hemagglutinin stem could dissipate the threat within five to ten years if development is aggressively pursued.
- Historical health improvements have extended life expectancy from 26 years in 1800 to 80 years in the U.S. today, driven by the Human Genome Project, a 13-year, $3.8 billion investment expected to eventually prevent over 4,000 genetic diseases.
- Bioscience investments are projected to solve global issues including clean water and bioterrorism defense, though adjusted for inflation, U.S. federal investment since 1998 has decreased despite a cumulative $200 billion incremental investment.
- Global health initiatives like PEPFAR aim to treat 5.3 million people, preventing 250,000 people and 230,000 babies from contracting HIV last year, while measles immunization scaled over the last decade has prevented four million child deaths.
- Polio cases have been reduced from 350,000 in 1988 to 223 in 2012, with eradication expected to cost $100 million annually compared to previous estimates of $100 billion, providing a model for sustainability and equity.
- Healthcare costs are projected to continue skyrocketing and potentially bankrupt the U.S. if Americans do not achieve better health, necessitating a balanced portfolio of research and usage programs to prevent deaths from cancer, infections, and injuries.
- The convergence of nanotechnology, engineering, and medicine is expected to revolutionize the diagnosis and treatment of Alzheimer's, cancer, and other diseases, with the potential for innovation in bioscience exceeding previous levels.